MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that initial data from its ongoing

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 27, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three poster presentations at the 38th Annual Meeting of the

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that clinical data from expansion cohorts in its Phase 1

Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO Monrovia, Calif. – June 1, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it will present new data from pre-clinical studies evaluating XmAb®5574, an Fc engineered monoclonal

Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings Monrovia, Calif. – April 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical CD19 program for lymphoma and leukemias at the Annual Meeting of the

Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference Monrovia, Calif. – December 2, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485

First clinical data from a candidate developed using Xencor's antibody engineering platform

MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb ®

PASADENA, Calif. --(BUSINESS WIRE)--Mar. 14, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb ® CD28

MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 8, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on two novel XmAb ®